Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.28%72.671.2%$696.83m
CELGCelgene Corporation
-4.70%111.871.3%$645.43m
AMGNAmgen Inc.
-3.40%140.171.0%$605.61m
BIIBBiogen Inc.
-2.33%284.381.2%$526.97m
REGNRegeneron Pharmaceuticals, Inc.
-2.85%358.453.6%$382.78m
ALXNAlexion Pharmaceuticals, Inc.
0.73%125.071.9%$363.71m
ILMNIllumina, Inc.
-3.51%121.963.0%$177.14m
VRTXVertex Pharmaceuticals Incorporated
-3.11%75.692.9%$164.83m
INCYIncyte Corporation
-3.79%103.152.4%$161.54m
TSROTESARO, Inc.
-2.60%136.2417.1%$156.34m
IONSIonis Pharmaceuticals, Inc.
-3.52%45.7810.0%$147.58m
EXELExelixis, Inc.
-9.21%16.576.4%$116.16m
BMRNBioMarin Pharmaceutical Inc.
-1.84%81.474.5%$114.14m
BLUEBluebird Bio, Inc.
-9.44%71.5023.3%$112.20m
AAgilent Technologies, Inc.
-0.07%44.811.6%$111.54m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel oncology therapies that target the tumor microenvironment. Its investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. Halozyme Therapeutics was founded by Gregory Ian Frost in 1998 and is headquartered in San Diego, CA.